IRAY TECHNOLOGY(SH:688301) ZHONGTAI SECURITIES·2025-10-29 06:36Investment Rating - The report maintains an "Accumulate" rating for the company, indicating a positive outlook for the stock over the next 6 to 12 months [3][8]. Core Views - The company reported strong performance in Q3 2025, with revenue reaching 1.549 billion yuan, a year-on-year increase of 14.22%, and a net profit attributable to shareholders of 471 million yuan, up 20.61% year-on-year. In Q3 alone, revenue was 482 million yuan, reflecting a significant growth of 46.18% year-on-year, and net profit increased by 64.43% [4][5]. - The growth in revenue is attributed to several factors, including the domestic medical equipment replacement policy, stable partnerships with leading dental equipment manufacturers, and increased demand in industrial testing from lithium battery manufacturers [6][7]. - The company has maintained a high level of R&D investment, with R&D expenses amounting to 228 million yuan in the first three quarters of 2025, accounting for 14.71% of revenue [7][8]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.549 billion yuan, with a net profit of 471 million yuan. The Q3 results showed a revenue of 482 million yuan and a net profit of 136 million yuan [4][5]. - The sales gross margin was 51.98%, a decrease of 2.30 percentage points year-on-year, while the net profit margin improved to 29.48%, an increase of 1.57 percentage points [6]. Growth Drivers - The company benefited from the domestic medical device replacement policy, which boosted demand in the medical imaging sector. Additionally, it became a major supplier in the Korean dental CBCT market, contributing to the recovery of its dental business [6][7]. - New core components and solutions saw significant growth, with some areas exceeding 50% year-on-year growth [6]. R&D and Innovation - The company continues to invest heavily in R&D, with a focus on new technologies and products. In the first half of 2025, it filed 28 new intellectual property applications, including 14 invention patents [7][8]. - As of June 2025, the company had a total of 594 registered or authorized intellectual properties, including 198 invention patents [7]. Future Outlook - The report projects that the company's net profit attributable to shareholders will reach 642 million yuan in 2025, 793 million yuan in 2026, and 963 million yuan in 2027, with corresponding P/E ratios of 38.7, 31.4, and 25.8 [8][10].